Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

About | View Sample | Privacy

Hottest Products

Compare Top Solutions in:

Evaluate more than 400,000 products >>

Featured Jobs

Analyst, Procurement Operations Job
Celgene Corporation - Basking Ridge, NJ, US
Laboratory Facility Manager
International AIDS Vaccine Initiative - New York, NY
Director, IT Global Operation Services, End-User Informatics Job
Celgene Corporation - Summit, NJ, US
Hematology Oncology Consultant, Hematology - Louisiana North Job
Celgene Corporation - Louisiana, LA, US
Clinical Trials Site Director
Lovelace Respiratory Research Institute - Albuquerque, NM

More Jobs >>

Events

New Paradigms to Fund & Move Biotech
January 11-12, 2012 — San Francisco, CA
Health Market Science Webinar: 3 Steps to New Physician Opportunities
Nov. 17
Enforcement, Litigation and Compliance Conference
Dec. 6-7 — Washington, DC
Biomarker Applications for Improved Clinical Trial Outcomes
Nov. 15-16 — Boston

More Events >>

Related Tags >> Synagis AstraZeneca

motavizumab News

Most Popular motavizumab Story

Motavizumab failure shifts spotlight to RSV vaccines

December 23, 2010 — 8:51am ET | By John Carroll

The news this week that AstraZeneca ($AZN) is writing off its big motavizumab program for RSV has shifted the spotlight to a slate of earlier stage compounds as well as vaccines. The Wall Street Read more...

motavizumab Press Releases

MedImmune Receives FDA Complete Response Letter on Motavizumab

Latest Headlines

Motavizumab failure shifts spotlight to RSV vaccines
December 23, 2010

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>

THE FIERCEMARKETS NETWORK